ImmuneBridge

About ImmuneBridge

ImmuneBridge is focused on developing a new generation of allogeneic cell therapies to make cancer cures accessible to everyone, leveraging nature's innate intelligence to eliminate cancer.

Products & Services

Allogeneic Cell Therapies:A new generation of therapies aimed at making cancer cures accessible to all.

Proprietary Expansion Technology:Technology that amplifies cord blood-derived immune stem cells while maintaining immune multipotency, creating a diverse, consistent, and abundant cellular source for immunotherapies.

Specialties

Allogeneic Cell Therapies Immunotherapy Cord Blood-Derived Immune Stem Cells

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 12000000 MR: - FA: $12 million FAN: 12000000	D: 2023-04-11 FD: 2023-04-11	4 investors

Seed Latest

2023-04-11

$12.0M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

N

Nina Horowitz

CHIEF EXECUTIVE OFFICER

R

Rui Tostoes

CHIEF TECHNOLOGY OFFICER

G

Grace Eppolito

SENIOR SCIENTIST, PARTNERSHIPS

J

James Liu

Scientist

M

Miguel Madero

VP OF SOFTWARE AND DATA

A

Albina Popova

CHIEF OF STAFF, HEAD OF OPS

View 18 more team members with Pro

Unlock Full Team Directory

Recent News

ImmuneBridge Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised